Background: Clostridioides difficile resistant to macrolide-lincosamide-streptogramin B (MLS B ) has not been reported in China. Methods: In a cross-sectional study in two tertiary hospitals, C. difficile isolates from stool specimens from community-onset, hospital-associated diarrheal patients were analyzed for toxin genes, genotype, and antibiotic resistance, and the patients' clinical charts were reviewed. 
Background: Clostridioides difficile resistant to macrolide-lincosamide-streptogramin B (MLS B ) has not been reported in China. Methods: In a cross-sectional study in two tertiary hospitals, C. difficile isolates from stool specimens from community-onset, hospital-associated diarrheal patients were analyzed for toxin genes, genotype, and antibiotic resistance, and the patients' clinical charts were reviewed. 
Introduction
Clostridioides difficile, an anaerobic, gram-positive, spore-forming bacterium, causes severe infectious colitis, toxic megacolon, and sepsis, which are life threatening, and it is also responsible for antibiotic-associated diarrhea exhibiting asymptomatic carriage or mild manifestations. 1 Clostridioides difficile infection (CDI) affects approximately more than 300,000 hospitalized patients each year [2] [3] [4] [5] [6] and has become the leading cause of hospital-acquired diarrhea worldwide. 7, 8 Exposure to antibiotics is considered the most important modifiable risk factor for the development of CDI. 9 Antibiotic resistance of C. difficile also plays a key role in driving the emergence of new strain types. C. difficile PCR ribotype 027 has a high correlation with fluoroquinolone resistance, leading to its widespread distribution in North America and Europe. 10 Metronidazole and vancomycin remain the first-line therapeutics for CDI despite the emergence of sporadic metronidazole-and vancomycin-resistant C. difficile. 10 Resistance to macrolide-lincosamide-streptogramin B (MLS B ) is considered an important factor not only driving the persistence and transmission of C. difficile but also increasing the risk for CDI in patients. 11 Recently, the rate of MLS B resistance has been significantly increasing worldwide. The antibiotic resistance profile of C. difficile in 2012-2015 revealed that the rate of erythromycin (ERY) resistance ranged from 13% to 100% and that of clindamycin (CLI) resistance ranged from 8.3% to 100%. 10 The emergence of CLI-resistant 027 has been found to be a new strain type increasing the risk of CDI and accelerating its spread in Europe. 11, 12 In 2001, a CLI-resistant, toxin A-negative, and toxin B-positive (A − B + ) C. difficile clone with the ermB gene has been reported be associated with a nosocomial outbreak in the Netherlands. This clone was also a potential predictor of enhanced CDI in Poland. 13 A systematic review and metaanalysis from 2010 to 2016 in China showed that the rate of ERY and CLI resistance was 80.2% and 81.7%, respectively. 14 A cross-sectional study in Eastern China in 2012-2015 revealed that resistance to ERY and CLI was 64.7% and 62.5%, respectively, with significantly different distribution in different genotypes.
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MLS B -type antibiotic resistance is due to posttranscriptional methylation of 23S ribosomal rRNA. 16 The resistance of C. difficile to ERY and CLI has been described to be transferred with no involvement of plasmid DNA. The resistance of C. difficile to ERY and CLI is encoded by the erythromycin resistance methylase gene (ermB) located on the mobilizable non-conjugative transposon Tn 5398. 16, 17 However, ermB genes have not been identified in all clinical C. difficile isolates expressing high resistance to ERY and CLI, which might be conferred by other mechanisms. Moreover, the data on MLS B resistance of C. difficile in China are limited. The rate of MLS B resistance and the correlation between genotypes and MLS B resistance and between C. difficile carrying ermB genes and virulence properties are still unclear.
The present cross-sectional study in community-onset, hospital-associated diarrheal patients from two hospitals in Eastern China was conducted to reveal the correlations among toxin genes, MLS B resistance, and ermB genes. We also analyzed the difference in CDI severity induced by different genotypes with MLS B resistance. 
Materials and Methods

Sample Collection
Clostridioides difficile Culture
Stool specimens were treated with alcohol, and then the mixture was inoculated onto cycloserine-cefoxitin fructose agar with selective supplement (Oxoid, Basingstoke, UK) as previously reported. 15 The isolates were identified by morphological characteristics of flat, yellow, ground-glass appearance, and special odor on the CCFA. 22 C. difficile was further confirmed using the latex agglutination test (Oxoid, Ltd., Basingstoke, UK). All isolates were stored at −70°C in the brain-heart infusion broth with 10% glycerol until subsequent analyses.
Detection of C. difficile Toxin and ermB Genes
Genomic DNA of C. difficile was extracted using the QIAamp DNA Blood Mini Kit (Valencia, CA, USA), according to the manufacturer's instructions. The toxin genes tcdA and tcdB and the housekeeping gene tpi were detected using a conventional polymerase chain reaction (PCR) assays with the primer sequences reported previously. 15 The ermB gene was detected by the conventional PCR assay as previously reported. 13 After PCR amplification, the PCR products were analyzed by agarose gel electrophoresis. The tcdA-F and tcdA-R primers were used to detect the tcdA gene, yielding a 369 bp amplicon for tcdA-positive strains or a 110 bp amplicon for tcdAnegative strains. The PCR product of ermB gene was 688 bp. Two standard C. difficile strains (ATCC 43255 and 700057) obtained from the American Type Culture Collection (ATCC; Manassas, VA, USA) were used as the positive and negative controls for both tcdA and tcdB, respectively. The blank, positive, and negative controls were examined in each test simultaneously.
Multilocus Sequence Typing
Six reference C. difficile strains, namely, ATCC 43255, 43598, BAA-1870, BAA-1803, BAA-1801, and 700057, were used as the controls. All C. difficile isolates were genotyped by multilocus sequence typing (MLST) as described previously. 23 In brief, seven loci, namely, adk, atpA, dxr, glyA, recA, sodA, and tpi, widely distributed on the chromosome, were amplified by the PCR. The PCR products were sequenced using the 3730 XL DNA Analyzer (Applied Biosystems). All the sequences according to the seven loci were input into the C. difficile MLST database (http://pubmlst.org/cdifficile) for determining the sequence types (STs). A minimal spanning tree was constructed using Bionumerics software version 5.1 (Applied Math, Austin, TX, USA).
Antibiotic Susceptibility Testing
The isolates of C. difficile were tested for resistance to metronidazole, vancomycin, clindamycin, and erythromycin by agar dilution as previously reported. 24 Bacteroides fragilis (ATCC 25285) and C. difficile (ATCC 700057) were included in each run as the controls. The minimal inhibitory concentration (MIC) results were interpreted following the guidelines of the Clinical and Laboratory Standards Institute (CLSI) published in 2017 for metronidazole and clindamycin. 24 The breakpoints for vancomycin and erythromycin were determined according to a previous study. 25 
Data Analysis
The data were analyzed using Statistical Package for Social Sciences (SPSS, Chicago, IL, USA) version 19.0 and Epi Info version 3.5.1. The difference in CDI severity score among different genotypes was analyzed using the nonparametric test. Logistic regression analysis was used to identify independent risk factors. The odds ratio (OR), 95% confidence interval (CI), and P-values were calculated to assess the differences in clinical characteristics between A + B + and A − B + isolates resistant to CRY and CLI. The results with P-values < 0.05 were considered statistically significant.
Results
Clinical Information of Diarrheal Patients from Two Hospitals
A total of 1250 patients with diarrhea at the HFPH (n = 1053) and LSPH (n = 197) were enrolled in this cross-sectional study conducted over five months. One stool specimen was collected from each patient, with no duplicated specimens, when the patients were admitted within less than 24 h. We recovered a total of 190 (15.2%) isolates (HFPH, n = 141; LSPH, n = 49) with the tpi gene from these stool specimens. All the isolates were toxigenic C. difficile carrying either or both tcdA and tcdB; no nontoxigenic isolates were found ( Figure 1 ). All the clinical information, including basic information and immunebiochemical data, was compared between the patients from the HFPH and LSPH (Table 1 ). All 190 patients had CA CDI. The CDI rate in patients from the HFPH was 13.4%, which was significantly lower than that in patients from the LSPH (24.9%) (χ 2 = 20.40, P < 0.0001). The patients enrolled in this study were mainly from the wards of infectious diseases, psychiatry and neurology, and blood and cardiology in the LSPH; however, the wards of gastroenterology, infectious disease, and pediatrics were the main sources in the HFPH, which resulted in the difference in ward distribution between the LSPH and HFPH (χ 2 = 429.22, P < 0.0001).
CDI Severity
The clinical data of all the enrolled patients were assessed via blinded chart review by physicians as reported previously. 15, 20, 21 No case was categorized under the CDI severity scores of 1, 5, and 6. Furthermore, 69.5% of CDI was categorized under the severity score 2 and 22.6% was under the severity score 3. Only 15 (7.9%) patients with CDI presented moderate clinical symptoms graded as CDI severity score 4. All the isolates were subjected to further analysis ( Figure 1) .
Genotype of C. difficile Isolates
Of the 190 toxigenic C. difficile, 102 (53.7%) isolates were positive for tcdA and tcdB (A + B + ), in which ST3, ST35, and ST54 were the dominant genotypes. The 88 (46.3%) isolates were negative for tcdA but positive for tcdB (A − B + ), among which three STs were ST37, ST39, and ST81. All the isolates were divided into 18 STs, indicating a high genetic diversity of C. difficile in these two hospitals, resulting in the difference in ST distribution between these hospitals (χ 2 = 6.02, P = 0.049) ( Table 2) .
A minimal spanning tree was constructed to reveal the allelic difference among isolates. As shown in Figure 2 , two independent clusters (A and B) were obviously divided in the minimal spanning tree. The cluster A presented high diversity within 14 STs, and seven of them were completely resistant to MLS B . Half of the ST8 and ST233 isolates were susceptible to MLS B , and the other four STs had lower resistance rates, ranging from 6.5% to 33.3%. ST11 and all the A in cluster A in a disorderly manner, and no genetic relationship between MLS B -resistant and MLS B -susceptible C. difficile isolates was found. There were no differences on distribution of MLS B -resistant C. difficile isolates between two hospitals (χ 2 = 3.13, P = 0.077), indicating that this clone was a common genotype in community associated CDI in Eastern China (Table 2) .
Antibiotic Resistance and ermB of Isolates
The antibiotic-susceptibility pattern of 190 toxigenic C. difficile isolates is presented in /L) count of <100, respectively. There were no significant differences among different ages ranging from >20 to >80 years of age. However, we notably found that CDI induced by MLS B -resistant A (Table 4 and Table S1 ). The average CDI severity scores induced by ermB-positive isolates in A − B + C. difficile were significantly higher than those induced by the ermB-positive isolates in A + B + C. difficile isolates (Z = −4.68, P < 0.001) (Table S1 ) and ermB-negative isolates in A − B + C. difficile isolates (Z = −2.41, P = 0.016) (Table 4) , respectively. However, no statistically significant differences were found between the ermB-positive and ermB-negative A in the ermB-negative isolates (Z = −1.11, P = 0.267) ( Table S1 ). The above results showed that ermB-positive A − B + C. difficile isolates with MLS B -resistance led to more severe CDI cases than others. Table 5 ). There were statistically significant differences in the CDI severity scores among different STs in the ermB-positive isolates (x 2 = 36.77, P = 0.001) ( Table 5 ). In patients with a CDI severity score of 4, a total of 9 ST37 genotype isolates (75.0%, 9/12), one of A − B + C. difficile, was found, which was more frequently than other STs, and the number of ST37 increased with the CDI severity score (x 2 = 26.38, P < 0.001) ( Table 5 ). In ermB-negative isolates, only one 
Discussion
CDI is increasingly becoming a public health concern worldwide. During recent years, several studies conducted in China have revealed that CDI might gradually be a leading intestinal infection related to antibiotic usage. Furthermore, more attention should be paid to the antibiotic resistance of C. difficile in China, following the clarification of the molecular epidemiology of CDI. To the best of our knowledge, this is the first study to disclose the molecular characteristics of toxigenic C. difficile resistant to MLS B in community acquired CDI patients in Eastern China to address the different genotypes resulting in various CDI severities. In this study, we found that C. 17 The strains of C. difficile carried over 50% of MLS B resistance rates with high-level resistance in Asia, and the MIC 90 (mg/L) was equal to or more than 128 mg/L, except in a study in Taiwan. 26 Antibiotic resistance data for C. difficile strains are still not enough to reveal the accurate antibiotic resistance profile in China. MLS B resistance data over the last 10 years showed that the average rate of resistance to ERY and CLI was 80.2% and 81.7% in China mainland, respectively. Our previous study results showed that the MLS B resistance rates in Zhejiang were lower than those observed in Shanghai. 15, 27 Resistance to MLS B enhanced the risk of CDI and promoted the persistence and transmission of C. difficile. The 
